WAPG announces new partnerships with leading firms to secure free tax and legal advisory services for early-stage life sciences and healthcare companies Kumar Jeetendra | January 29, 2022 Today, We are Pioneer Group (WAPG) launches new nationwide partnerships with Leyton, the UK’s largest innovation funding consultancy, and leading UK law firm, Mills & Reeve. As a result of the innovative partnership, start-up ventures taking part in the WAPG business accelerator programme will gain free expert tax and legal advisory services. Free credits will …
Alembic Pharmaceuticals receives USFDA Final Approval for Clarithromycin Tablets USP, 250 mg and 500 mg. Kumar Jeetendra | February 1, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clarithromycin Tablets USP, 250 mg and 500 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Biaxin Filmtab Tablets, 250 mg and 500 …
Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Final Approval for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. Kumar Jeetendra | March 8, 2022 8th March 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. The approved ANDA is therapeutically equivalent to the reference …
Alembic Pharmaceuticals receives USFDA Tentative Approval for Macitentan Tablets, 10 mg. Kumar Jeetendra | March 14, 2022 14th March 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Macitentan Tablets, 10 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Opsumit Tablets, 10 mg, of …
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Clobetasol Propionate Foam, 0.05%. Kumar Jeetendra | April 28, 2022 25th April 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Foam, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product …
Cipla Launches ‘RT Direct’ Multiplex real time PCR kit for Covid-19 RNA extraction free kit to deliver results in just 45 Min Kumar Jeetendra | May 10, 2022 Mumbai, India; May 10, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me Pvt. Ltd. With this, Cipla is expanding its diagnostics offering to bring more advanced and innovative products. Cipla will be responsible …
Scale up your chemistry, scale down your water consumption Kumar Jeetendra | July 4, 2022 Developed in response to customer demand, the new CondenSyn MAXI from Asynt is ideal for larger scale synthetic chemical reactions and is the latest addition to their popular laboratory air condenser range which is proven in tens of thousands of installations worldwide. The CondenSyn MAXI enables scientists to scale up their experiments effectively from small …
Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru Kumar Jeetendra | July 7, 2022 Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022. The facility, spread across 340,000-square feet, …
Fast Tracking Flowmeter Design for the Measurement of Fuel Consumption Kumar Jeetendra | July 7, 2022 With increasing fuel prices, all sectors of the transport industry, from small trucks to larger super-tankers, are taking an interest in effective ways of measuring their vehicle’s fuel consumption and hydraulic oil flow. Unfortunately, it’s not a simple task! Engine fuel consumption and efficiency generally goes unmonitored, the performance of a diesel power unit assessed …
Cipla receives USFDA approval for generic version of Revlimid® (lenalidomide capsules) Kumar Jeetendra | September 7, 2022 Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (US FDA). Cipla’s Lenalidomide …
‘Listen to the Future’- Cipla’s digital film reinforces its ESG commitments Kumar Jeetendra | September 14, 2022 Mumbai, India, 14th September: Cipla Limited launched a thought-provoking brand film ‘Listen to the Future’ to reiterate the company’s ESG goals for 2030. To bring alive its ethos of contributing toward a greener environment and sustainable value creation, the film creatively highlights the importance of positive actions through the lens of children. The brand film …
Alembic Pharmaceuticals receives USFDA Final Approval for Paclitaxel Injection USP Kumar Jeetendra | October 27, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) Multiple-Dose Vials. This is the first product approval …
